Researchers report startling glaucoma protein discovery

October 20, 2017 by Ben Brumfield, Georgia Institute of Technology
The newly discovered Y-shape at the base of myocilin joins together four well-known protein shapes called olfactomedins, or propellers, in groups of four. Understanding myocilin is important to certain kinds of hereditary glaucoma. The artist of this depiction, Raquel Lieberman, is the principal investigator of the team that confirmed a Y-shaped structure, the first ever found that was encoded as such by a gene and not constructed out of protein component parts. Credit: Georgia Tech / Raquel Lieberman

A discovery in a protein associated with glaucoma was so unheard of that for over two years, researchers ran it through a gauntlet of lab tests and published a new research paper on it. The tests validated what they initially saw.

It was a Y-shape. That made it an extreme oddity significant to science, and possibly someday to medicine, too, particularly in the treatment of certain types of blindness.

"A protein like this one has never been reported before. There are extremely few Y-shapes in proteins at all," said Raquel Lieberman, who led the study. Lieberman is a structural biologist at the Georgia Institute of Technology, and an expert on myocilin, a protein sometimes implicated in a form of hereditary .

Glaucoma is the second most common cause of blindness globally, and hereditary glaucoma is just one category of the disease. Genetic mutations in myocilin are a major cause of hereditary glaucoma, which can strike at a particularly young age, including in childhood.

There are other shapes in proteins that look similar to the Y, but there are key differences.

"Antibodies look a little like this, but in antibodies, separate proteins that are the products different genes fit together to make a kind of Y-shape," Lieberman said. "This Y is encoded by one single gene sequence. That makes this absolutely unique."

In addition to being the ostensible unicorn of protein structures, it turned out to be the central binding element of myocilin. The Y ties together major components to nail down myocilin's overall form, overturning previous conceptions about the protein's appearance.

Although the Y hasn't been particularly implicated in glaucoma, its existence could meaningfully alter the way researchers understand myocilin and how it works in the eye. When myocilin goes wrong, or "misfolds," it makes fibrils that damage tissue called the trabecular meshwork that normally allows the fluid inside the eye to drain and relieve interior pressure.

"If you kill the cells that make this drainage work, it's going to clog, and pressure inside the eye will increase," said Lieberman, who is an associate professor in Georgia Tech's School of Chemistry and Biochemistry. That pressure can kill parts of the retina or optic nerve, leading to irreversible partial or total blindness.

But though myocilin is common in many parts of our bodies, its normal, healthy role in the eye and, for that matter, what functions the protein has in the body at all are still a mystery.

"I think if we knew what this protein was doing in the trabecular meshwork, we would understand much more about glaucoma in general," Lieberman said. "This research lets us know more about what myocilin is."

Lieberman published her results on October 19, 2017, in the journal Structure. The research was funded by the National Eye Institute and the National Institute of General Medical Sciences, both at the National Institutes of Health, by the National Science Foundation, and by the U.S. Department of Energy Office of Science.

The road to blindness via glaucoma: A depiction of how blockage of fluid flow in the trabecular meshwork, located near the cornea, can lead to pressure build-up in the aqueous humor of the eye, resulting in optic nerve and retinal damage. Credit: BrightFocus Foundation

The focus of studies so far has been on a part of myocilin that is the main culprit in a form of hereditary glaucoma, a protein structure called the olfactomedin domain, which Lieberman has also studied extensively. It looks like a protein propeller with five blades that surround a hole in the center.

"When a myocilin propellor misfolds, it unravels and forms amyloid fibrils (stringy abnormal proteins) that kill cells that maintain the trabecular network," Lieberman said. "Until now, our work led us to believe that the propellers floated around individually as independent units, and not bound together in groups."

"All we knew before was that, in solution, those olfactomedins were just monomers. They didn't seem to make up anything of a higher order, except when they unraveled into amyloid fibers, stuck together and blocked fluid flow," Lieberman said.

The Y alters the picture.

It anchors the propellers in groups of four. Two propellers (olfactomedin domains) each appear to be connected to either tip of the Y's branches probably by amino acid strings. With the Y, the overall myocilin looks four pinwheels on strings tied to a slingshot.

Adding to the new discoveries: The Y itself is sticky, like glue. It's even annoying to handle in the lab.

"It was sticking to the plastic, sticking to the glass, sticking to the membrane, to beads," Lieberman said. "It's super sticky. That may serve a biological function."

Perhaps the Y fastens the propellers to surfaces. It's not yet known. "But we think the main function is to pair and separate out these olfactomedin domains," Lieberman said.

A depiction of the newly discovered Y-shape (tripartite) at the center of myocilin, a protein commonly studied in hereditary glaucoma. It is a dimer of dimers and a tetramer of coiled coils and the first directly genetically produced Y shape to be discovered. Credit: Georgia Tech / Lieberman lab

Mutations in the Y aren't significantly associated with glaucoma. "When it mutates, it misfolds, but not in a way that causes all that cell death," Lieberman said.

But in its normal role, the Y just might promote the speed of misfolding of the propeller protein (olfactomedin domain) that's implicated in hereditary glaucoma. When misfolded proteins come into contact with good proteins, the misfolded ones tend to make the good ones misfold, too.

"If these propeller proteins are clustered together because of the Y, and one of them misfolds, it's going to recruit the others," Lieberman said. "Having them tied together in groups will only magnify the contagion."

The Y-shape, also termed tripartite, is made up of what are called "coiled coils." They're pairs of short coils, a bit like two pieces of Slinky or coiled telephone cords, and they can be stretched similarly to a Slinky and then contract back in a similar way.

Coiled coils are very common in our bodies.

"Coiled coils represent three to five percent of our genome," Lieberman said. "They're found in muscle contraction, in molecule transport up and down neurons. Lots of extracellular proteins (proteins that function outside of cells) also have them."

The Y's branches are each a pair of coiled coils, each called a dimer, and in the trunk, they come together to form a group of four coiled coils called a tetramer.

Explore further: 3D structure solved for vulnerable region of glaucoma-causing protein

More information: Structure and Misfolding of the Flexible Tripartite Coiled-Coil Domain of Glaucoma-Associated Myocilin. Structure. DOI: dx.doi.org/10.1016/j.str.2017.09.008

Related Stories

3D structure solved for vulnerable region of glaucoma-causing protein

April 22, 2015
Scientists have determined the three-dimensional structure of a key part of a protein that is associated with glaucoma and identified regions of this domain that correlate with severe forms of the disease.

Researchers use CRISPR engineering to prevent certain glaucoma in mice

October 2, 2017
A University of Iowa-led team of researchers has used the gene editing method called CRISPR-Cas9 to disrupt a mutant gene that is responsible for some forms of glaucoma, one of the most common causes of irreversible blindness.

Focus on glaucoma origins continues path toward potential cure

January 17, 2012
Glaucoma is the second leading cause of blindness. Nearly 4 million Americans have the disorder, which affects 70 million worldwide. There is no cure and no early symptoms. Once vision is lost, it's permanent.

Researchers discover potential drug targets for early onset glaucoma

January 23, 2014
Using a novel high-throughput screening process, scientists have for the first time identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma.

Recommended for you

Scientists combine technologies to view the retina in unprecedented detail

November 14, 2018
By combining two imaging modalities—adaptive optics and angiography—investigators at the National Eye Institute (NEI) can see live neurons, epithelial cells, and blood vessels deep in the eye's light-sensing retina. Resolving ...

Eyepatch with dissolvable needles used to treat eye disease

November 12, 2018
A team of researchers affiliated with several institutions in Singapore has developed an eyepatch with dissolvable needles for use in treating eye diseases. In their paper published in the journal Nature Communications, the ...

Calcifications in the eye increase risk for progression to advanced AMD by more than six times

November 8, 2018
Calcified nodules in the retina are associated with progression to late stages of age-related macular degeneration (AMD). Experts from Queen's University Belfast, working in partnership with the University of Alabama of Birmingham ...

Traditional glaucoma test can miss severity of disease

November 8, 2018
The most common tests for glaucoma can underestimate the severity of the condition by not detecting the presence of central vision loss, according to a new Columbia University study.

New contact lens to treat eye injuries

November 5, 2018
A new therapeutic contact lens that acts as a bandage for eye surface injuries being developed by QUT researchers could soon fast track the healing of previously difficult to treat corneal wounds.

New study offers hope for patients suffering from a rare form of blindness

November 1, 2018
A new form of therapy may halt or even reverse a form of progressive vision loss that, until now, has inevitably led to blindness. This hyper-targeted approach offers hope to individuals living with spinocerebellar ataxia ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.